524711 — Vista Pharmaceuticals Income Statement
0.000.00%
- IN₹664.76m
- IN₹706.87m
- IN₹102.88m
- 26
- 16
- 51
- 18
Annual income statement for Vista Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 228 | 12.7 | 3.95 | 10 | 103 |
Cost of Revenue | |||||
Gross Profit | -11.8 | 5.36 | 0.28 | -18.2 | 14 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 289 | 37.2 | 22.2 | 60.7 | 146 |
Operating Profit | -61.4 | -24.6 | -18.3 | -50.6 | -42.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -39.4 | -36.9 | -25.6 | -58.8 | -51.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -36.8 | -18.9 | -8.32 | -56.6 | -45.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -36.8 | -18.9 | -8.32 | -56.6 | -45.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -36.8 | -18.9 | -8.32 | -56.6 | -45.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.21 | -0.544 | -0.226 | -1.54 | -1.03 |